Cargando…

Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor–Containing Regimen. Etraswitch Study

BACKGROUND: Etravirine (ETR) was approved for patients with virological failure and antiretroviral resistance mutations. It has also shown antiviral efficacy in antiretroviral-naïve patients. However, data on the switching from protease inhibitors (PI) to ETR are lacking. METHODS: HIV-1-infected pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Echeverría, Patricia, Bonjoch, Anna, Puig, Jordi, Moltó, José, Paredes, Roger, Sirera, Guillem, Ornelas, Arelly, Pérez-Álvarez, Nuria, Clotet, Bonaventura, Negredo, Eugènia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913576/ https://www.ncbi.nlm.nih.gov/pubmed/24503952 http://dx.doi.org/10.1371/journal.pone.0084676

Ejemplares similares

High Prevalence of Sarcopenia in HIV-Infected Individuals
por: Echeverría, Patricia, et al.
Publicado: (2018)

Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients
por: Echeverría, Patricia, et al.
Publicado: (2014)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity
por: Bonjoch, Anna, et al.
Publicado: (2016)

Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study
por: Bonjoch, Anna, et al.
Publicado: (2016)

A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
por: Negredo, Eugènia, et al.
Publicado: (2020)

Effectiveness of physically ablative and pharmacological treatments for anal condyloma in HIV-infected men
por: Vela, Sandra, et al.
Publicado: (2018)

Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner
por: Echeverría, Patricia, et al.
Publicado: (2014)

Association between lipid genetic and immunological status in chronically HIV-infected patients
por: Echeverría, Patricia, et al.
Publicado: (2014)

Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012)

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens
por: Kapadia, Shashi N, et al.
Publicado: (2018)

Remote Health Monitoring in the Workplace for Early Detection of COVID-19 Cases during the COVID-19 Pandemic Using a Mobile Health Application: COVIDApp.
por: Echeverría, Patricia, et al.
Publicado: (2021)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia
por: Llibre, Josep M., et al.
Publicado: (2015)

Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial
por: Balk, Jiska M, et al.
Publicado: (2015)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan
por: Negredo, Eugenia, et al.
Publicado: (2012)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

The use of a darunavir/ritonavir once-daily regimen in two pregnant women
por: Lambert, JS, et al.
Publicado: (2010)

Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study
por: Teeranaipong, Phairote, et al.
Publicado: (2016)

Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens
por: Potard, Valérie, et al.
Publicado: (2018)

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
por: Mulligan, Nikki, et al.
Publicado: (2016)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib
por: Lamba, M, et al.
Publicado: (2017)

Week 48 Results of EMERALD: A Phase 3, Randomized, Non-inferiority Study Evaluating the Efficacy and Safety of Switching from Boosted-protease Inhibitors (bPI) Plus Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Regimens to the Once Daily (QD), Single-tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-infected Adults
por: Orkin, Chloe, et al.
Publicado: (2017)

Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals
por: Juega-Mariño, Javier, et al.
Publicado: (2017)

Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications
por: Kubitza, Dagmar, et al.
Publicado: (2016)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content
por: Rubinstein, Samuel M., et al.
Publicado: (2020)

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)
por: Charpentier, Charlotte, et al.
Publicado: (2013)

DRV concentrations and viral load in CSF in patients on DRV/r 600/100 or 800/100mg once daily plus two NRTI
por: Di Yacovo, Silvana, et al.
Publicado: (2014)

Efficacy and Patient Satisfaction of Dipeptidyl Peptidase-4 Inhibitor After Switching From Once-Daily DPP-4 Inhibitor to Once-Weekly Regimen
por: Suzuki, Katsunori, et al.
Publicado: (2018)

Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity
por: Agneskog, Eva, et al.
Publicado: (2014)

Profile of etravirine for the treatment of HIV infection
por: Tseng, Alice, et al.
Publicado: (2010)

"Random" gentamicin concentrations do not predict trough levels in neonates receiving once daily fixed dose regimens
por: Boyle, Elaine M, et al.
Publicado: (2006)

Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
por: Moro-Álvarez, María J, et al.
Publicado: (2008)

Compliance with Once-Daily versus Twice or Thrice-Daily Administration of Antibiotic Regimens: A Meta-Analysis of Randomized Controlled Trials
por: Falagas, Matthew E., et al.
Publicado: (2015)

Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO
por: Molina, Jean-Michel, et al.
Publicado: (2014)

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
por: Bunupuradah, Torsak, et al.
Publicado: (2015)

Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4(+) T-cell immune recovery
por: Gómez-Mora, Elisabet, et al.
Publicado: (2017)

Prevalence of HPV-DNA and E6 mRNA in lung cancer of HIV-infected patients
por: Sirera, Guillem, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d391mlg5mpiiul3t15ro56c5uj